Cagrilintide vs Tirzepatide
Side-by-side comparison of Cagrilintide and Tirzepatide: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Cagrilintide
Tirzepatide
Cagrilintide
Cagrilintide (also known as AM833, development code NN9838) is a long-acting amylin analog developed by Novo Nordisk as a next-generation weight-management therapy, designed to be co-administered with the GLP-1 receptor…
Lowest listed price: $49.99 across 3 listings
Full Cagrilintide profileTirzepatide
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid…
Lowest listed price: $49.00 across 14 listings
Full Tirzepatide profileSide-by-side comparison
| Attribute | Cagrilintide | Tirzepatide |
|---|---|---|
| Category | Metabolic & Weight Loss | Metabolic & Weight Loss |
| Research Stage | Phase 3 | FDA Approved |
| Mechanism of Action | Cagrilintide engages both amylin and calcitonin receptor signaling with careful receptor selectivity profiling. Native amylin binds primarily to amylin receptors - heterodimeric complexes of the calcitonin receptor (CTR) with one of three receptor… | Dual GLP-1 and GIP Receptor Agonism Tirzepatide simultaneously activates two incretin receptors: the GLP-1 receptor and the GIP receptor. While the GLP-1 receptor component provides the well-established effects of GLP-1 agonism (glucose-dependent insulin… |
| Half-Life | ~159 hours (approximately 7 days) | ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification |
| Typical Dose Range | — | 2500 mcg (2.5 mg) starting dose, titrated every 4 weeks through 5000, 7500, 10000, 12500, to 15000 mcg (15 mg) maximum weekly dose |
| Dosing Frequency | Once weekly | Once weekly subcutaneous injection |
| Administration | — | Subcutaneous (weekly) |
| Side Effects | Cagrilintide's side-effect profile is dominated by gastrointestinal effects similar to but distinct from GLP-1 agonists, with some amylin-specific considerations. Most Common Side Effects (from trials): Gastrointestinal (dose-dependent): - Nausea: in the Phase… | Mild to moderate nausea (especially at initiation), headache, fatigue, constipation or diarrhea, abdominal distension. Injection site reactions. Rare: hypoglycemia, increased heart rate, pancreatitis. |
| Molecular Weight | 4246.7 g/mol | 4813.5 Da |
| Common Vial Sizes | — | 5mg, 10mg, 15mg |
Price History
2 data points- OF
- Half Nattys
Price History
3 data points- BM
- Half Nattys
- Ion Peptide
Cagrilintide: potential benefits
- Weight loss
- Appetite suppression (via different pathway than GLP-1)
- Glucagon suppression
- Complementary to GLP-1 agonists
Tirzepatide: potential benefits
- Mean body weight reduction of 22.5% at 72 weeks - highest of any anti-obesity medication (PMID: 35658024)
- 36.2% of participants achieved greater than or equal to 25% body weight loss (PMID: 35658024)
- Significant HbA1c reduction in type 2 diabetes (up to 2.4% at 40 weeks in the SURPASS-5 add-on-to-insulin trial) (PMID: 35133415)
- Potentially superior lean mass preservation versus GLP-1-only agents due to GIP component
- Dual incretin mechanism providing complementary metabolic benefits
- Improved lipid profiles including triglycerides, LDL cholesterol, and HDL cholesterol
- Reduction in waist circumference and markers of visceral adiposity (PMID: 37840095)
Frequently asked
What's the difference between Cagrilintide and Tirzepatide?
Cagrilintide is a metabolic & weight loss that cagrilintide engages both amylin and calcitonin receptor signaling with careful receptor selectivity profiling. native amylin binds primarily to amylin receptors - heterodimeric…. Tirzepatide is a metabolic & weight loss that dual glp-1 and gip receptor agonism tirzepatide simultaneously activates two incretin receptors: the glp-1 receptor and the gip receptor. while the glp-1 receptor component…. The two differ in mechanism, half-life (~159 hours (approximately 7 days) vs ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification), and typical dose range.
Which has the longer half-life, Cagrilintide or Tirzepatide?
Cagrilintide has a half-life of ~159 hours (approximately 7 days). Tirzepatide has a half-life of ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, Cagrilintide or Tirzepatide?
Lowest listed price on BodyHackGuide: Cagrilintide from $49.99, Tirzepatide from $49.00. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack Cagrilintide and Tirzepatide?
Stacking depends on mechanism overlap, safety profile, and goals. Cagrilintide and Tirzepatide should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Cagrilintide or Tirzepatide
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.